CLINICAL_TRIALS
trial_result
· 2025-10-30
Clinical Trial Update: Long-term Extension Study of Ligelizumab in Food Allergy [Phase 3]
Summary
A Phase 3 long-term extension study of ligelizumab in food allergy was terminated, and results were posted in 2025.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Food Allergy | Phase 3 | Status: TERMINATED | Results posted: 2025-10-30